Juglone (Synonyms: 5-Hydroxy-1,4-naphthalenedione)

Cat. No.: HY-N6949 Purity: 99.77%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Juglone (5-hydroxy-1,4-naphthalenedione) is a yellow dye that can be extracted from Juglans regia. Juglone induces apoptosis through the mitochondrial pathway. Juglone has antibacterial and antitumor activity .

For research use only. We do not sell to patients.

Juglone Chemical Structure

CAS No. : 481-39-0

Size	Stock	Quantity
Free Sample (0.1 - 0.2 mg)	Apply Now
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Juglone:

Juglone (Standard) Get quote

4 Publications Citing Use of MCE Juglone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	64 3 Compound: 6	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
A2780	GI₅₀	64 3 Compound: 6	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
A2780	IC₅₀	1.4 3 Compound: 14	Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay	[PMID: 19028102]
A2780	IC₅₀	1.4 3 Compound: 14	Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay	[PMID: 19028102]
A2780	GI₅₀	64 3 Compound: 6	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
A2780	IC₅₀	1.4 3 Compound: 14	Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay	[PMID: 19028102]
A549	IC₅₀	11.87 3 Compound: 7; JUG	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
A549	IC₅₀	11.87 3 Compound: 7; JUG	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
A549	IC₅₀	7 3 Compound: 1	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
A549	IC₅₀	7 3 Compound: 1	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
B16-F10	IC₅₀	6 3 Compound: 1	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
A549	IC₅₀	7 3 Compound: 1	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
B16-F10	IC₅₀	6 3 Compound: 1	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
B16-F10	IC₅₀	6 3 Compound: 1	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
BT-549	GI₅₀	> 100 3 Compound: 4	Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
BT-549	GI₅₀	> 100 3 Compound: 4	Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
BT-549	GI₅₀	>100 3 Compound: 4	Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
CAL-51	GI₅₀	> 100 3 Compound: 4	Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
CAL-51	GI₅₀	> 100 3 Compound: 4	Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
DU-145	IC₅₀	11.67 3 Compound: Juglone	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
CAL-51	GI₅₀	>100 3 Compound: 4	Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HBL-100	GI₅₀	66 3 Compound: 6	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
DU-145	IC₅₀	11.67 3 Compound: Juglone	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HCC1954	GI₅₀	6.44 3 Compound: 4	Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
EA.hy 926	IC₅₀	5.57 3 Compound: 7; JUG	Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
HaCaT	IC₅₀	0.8 3 Compound: 7d ; Juglone	Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line) Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)	[PMID: 9371243]
DU-145	IC₅₀	11.67 3 Compound: Juglone	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HCT-116	GI₅₀	4.2 3 Compound: 4	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
EA.hy 926	IC₅₀	5.57 3 Compound: 7; JUG	Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
HEK293	EC₅₀	1.7 3 Compound: 5	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HBL-100	GI₅₀	66 3 Compound: 6	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HCC1954	GI₅₀	6.44 3 Compound: 4	Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HBL-100	GI₅₀	66 3 Compound: 6	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HeLa	IC₅₀	65.46 3 Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 24631733]
HCC1954	GI₅₀	6.44 3 Compound: 4	Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HeLa	IC₅₀	68.46 3 Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 24631733]
HCT-116	GI₅₀	4.2 3 Compound: 4	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-116	GI₅₀	4.2 3 Compound: 4	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HeLa	GI₅₀	89 3 Compound: 6	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HCT-116	IC₅₀	31.6 3 Compound: Junglone	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
HCT-116	IC₅₀	31.6 3 Compound: Junglone	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
HEK293	EC₅₀	1.7 3 Compound: 5	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HeLa	IC₅₀	93.7 3 Compound: 1a	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
Hs 683	IC₅₀	7 3 Compound: 1	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
HeLa	GI₅₀	89 3 Compound: 6	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HEK293	EC₅₀	1.7 3 Compound: 5	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HT-29	IC₅₀	> 100 3 Compound: 1a	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	93.7 3 Compound: 44	Antitumor activity against human HeLa cells assessed as cell growth inhibition Antitumor activity against human HeLa cells assessed as cell growth inhibition	[PMID: 36858050]
HT-29	IC₅₀	7.71 3 Compound: Juglone	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HT-29	IC₅₀	7.71 3 Compound: Juglone	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HeLa	IC₅₀	15.73 3 Compound: 3	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 33766765]
HT-29	IC₅₀	> 100 3 Compound: 1a	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
K562	GI₅₀	> 100 3 Compound: 4	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HeLa	IC₅₀	68.46 3 Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 24631733]
HT-29	IC₅₀	> 100 3 Compound: 44	Antitumor activity against human HT-29 cells assessed as cell growth inhibition Antitumor activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 36858050]
LNCaP	IC₅₀	13.8 3 Compound: Juglone	Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 23643730]
HeLa	IC₅₀	65.46 3 Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 24631733]
HaCaT	IC₅₀	0.8 3 Compound: 7d ; Juglone	Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line) Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)	[PMID: 9371243]
HeLa	IC₅₀	93.7 3 Compound: 1a	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	13 3 Compound: 1	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
HeLa	IC₅₀	13 3 Compound: 14	Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells	[PMID: 19028102]
MCF7	IC₅₀	16.5 3 Compound: 1a	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
Hs 683	IC₅₀	7 3 Compound: 1	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
MCF7	GI₅₀	32.6 3 Compound: 4	Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HeLa	GI₅₀	89 3 Compound: 6	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
MDA-MB-231	IC₅₀	7.15 3 Compound: Juglone	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HeLa	IC₅₀	13 3 Compound: 14	Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells	[PMID: 19028102]
HT-29	IC₅₀	>100 3 Compound: 44	Antitumor activity against human HT-29 cells assessed as cell growth inhibition Antitumor activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 36858050]
HeLa	IC₅₀	15.73 3 Compound: 3	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 33766765]
MDA-MB-231	IC₅₀	75.76 3 Compound: 1a	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	7.71 3 Compound: Juglone	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HeLa	IC₅₀	65.46 3 Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 24631733]
MDA-MB-453	IC₅₀	27.52 3 Compound: 1a	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	>100 3 Compound: 1a	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	68.46 3 Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 24631733]
ME-180	IC₅₀	65.4 3 Compound: 1a	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
J774.2	IC₅₀	13.36 3 Compound: Junglone	Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
HeLa	IC₅₀	93.7 3 Compound: 1a	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
K562	GI₅₀	>100 3 Compound: 4	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MOLM-13	GI₅₀	21.9 3 Compound: 4	Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
KB	IC₅₀	6.55 3 Compound: 3	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 33766765]
HeLa	IC₅₀	93.7 3 Compound: 44	Antitumor activity against human HeLa cells assessed as cell growth inhibition Antitumor activity against human HeLa cells assessed as cell growth inhibition	[PMID: 36858050]
MV4-11	GI₅₀	0.06 3 Compound: 4	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
KB 3-1	IC₅₀	26.4 3 Compound: Junglone	Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
PC-3	GI₅₀	4.77 3 Compound: Juglone	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	[PMID: 30153964]
HepG2	IC₅₀	20.43 3 Compound: Juglone	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated upto 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated upto 48 hrs by MTT assay	[PMID: 38458106]
LNCaP	IC₅₀	13.8 3 Compound: Juglone	Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 23643730]
PC-3	GI₅₀	4.77 3 Compound: Juglone	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 28838831]
MCF7	GI₅₀	32.6 3 Compound: 4	Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
Hs 683	IC₅₀	7 3 Compound: 1	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
PC-3	IC₅₀	88.7 3 Compound: 1a	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
J774.2	IC₅₀	13.36 3 Compound: Junglone	Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
SK-MEL-28	IC₅₀	7 3 Compound: 1	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
MCF7	IC₅₀	16.5 3 Compound: 44	Antitumor activity against human MCF7 cells assessed as cell growth inhibition Antitumor activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36858050]
K562	GI₅₀	> 100 3 Compound: 4	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
SW1573	GI₅₀	50 3 Compound: 6	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
MCF7	IC₅₀	16.5 3 Compound: 1a	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
KB	IC₅₀	6.55 3 Compound: 3	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 33766765]
MCF7	IC₅₀	13 3 Compound: 1	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
T47D	GI₅₀	77 3 Compound: 6	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
U-373MG ATCC	IC₅₀	17 3 Compound: 1	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
KB 3-1	IC₅₀	26.4 3 Compound: Junglone	Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
MDA-MB-231	IC₅₀	75.7 3 Compound: 44	Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-231	IC₅₀	7.15 3 Compound: Juglone	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
LNCaP	IC₅₀	13.8 3 Compound: Juglone	Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 23643730]
WiDr	GI₅₀	81 3 Compound: 6	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
MCF7	GI₅₀	32.6 3 Compound: 4	Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MDA-MB-231	IC₅₀	75.76 3 Compound: 1a	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	13 3 Compound: 1	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
MDA-MB-231	IC₅₀	6.15 3 Compound: 7; JUG	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
MCF7	IC₅₀	16.5 3 Compound: 1a	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-453	IC₅₀	27.5 3 Compound: 44	Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition	[PMID: 36858050]
MCF7	IC₅₀	16.5 3 Compound: 44	Antitumor activity against human MCF7 cells assessed as cell growth inhibition Antitumor activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-453	IC₅₀	27.52 3 Compound: 1a	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	6.15 3 Compound: 7; JUG	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
ME-180	IC₅₀	65.4 3 Compound: 44	Antitumor activity against human ME-180 cells assessed as cell growth inhibition Antitumor activity against human ME-180 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-231	IC₅₀	7.15 3 Compound: Juglone	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
ME-180	IC₅₀	65.4 3 Compound: 1a	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	75.7 3 Compound: 44	Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 36858050]
MOLM-13	GI₅₀	21.9 3 Compound: 4	Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MDA-MB-231	IC₅₀	75.76 3 Compound: 1a	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MV4-11	GI₅₀	0.06 3 Compound: 4	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MDA-MB-453	IC₅₀	27.5 3 Compound: 44	Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition	[PMID: 36858050]
PC-3	GI₅₀	4.77 3 Compound: Juglone	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	[PMID: 30153964]
PC-3	GI₅₀	4.77 3 Compound: Juglone	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 28838831]
MDA-MB-453	IC₅₀	27.52 3 Compound: 1a	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	65.4 3 Compound: 1a	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
PC-3	IC₅₀	88.7 3 Compound: 44	Antitumor activity against human PC-3 cells assessed as cell growth inhibition Antitumor activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 36858050]
ME-180	IC₅₀	65.4 3 Compound: 44	Antitumor activity against human ME-180 cells assessed as cell growth inhibition Antitumor activity against human ME-180 cells assessed as cell growth inhibition	[PMID: 36858050]
PC-3	IC₅₀	88.7 3 Compound: 1a	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MOLM-13	GI₅₀	21.9 3 Compound: 4	Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
Platelet	IC₅₀	1.18 3 Compound: 7; JUG	Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
Platelet	IC₅₀	4.45 3 Compound: 7; JUG	Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
MV4-11	GI₅₀	0.06 3 Compound: 4	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
PC-3	GI₅₀	4.77 3 Compound: Juglone	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 28838831]
RPMI-8226	IC₅₀	3.95 3 Compound: 7; JUG	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
PC-3	GI₅₀	4.77 3 Compound: Juglone	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	[PMID: 30153964]
SK-MEL-28	IC₅₀	7 3 Compound: 1	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
PC-3	IC₅₀	88.7 3 Compound: 1a	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
SW1573	GI₅₀	50 3 Compound: 6	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
PC-3	IC₅₀	88.7 3 Compound: 44	Antitumor activity against human PC-3 cells assessed as cell growth inhibition Antitumor activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 36858050]
T47D	GI₅₀	77 3 Compound: 6	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
Platelet	IC₅₀	1.18 3 Compound: 7; JUG	Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
U-373MG ATCC	IC₅₀	17 3 Compound: 1	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
Platelet	IC₅₀	4.45 3 Compound: 7; JUG	Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
U-87MG ATCC	IC₅₀	7.45 3 Compound: 7; JUG	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
WiDr	GI₅₀	81 3 Compound: 6	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
RPMI-8226	IC₅₀	3.95 3 Compound: 7; JUG	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
SK-MEL-28	IC₅₀	7 3 Compound: 1	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
SW1573	GI₅₀	50 3 Compound: 6	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
T47D	GI₅₀	77 3 Compound: 6	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
U-373MG ATCC	IC₅₀	17 3 Compound: 1	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
U-87MG ATCC	IC₅₀	7.45 3 Compound: 7; JUG	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
WiDr	GI₅₀	81 3 Compound: 6	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]

In Vitro

Juglone (0-500 μg/mL, 15 h) shows significant antibacterial activity against Staphylococcus aureus, with MIC values ranging from 64-512 μg/mL^[1].
Juglone(5-20 μM, 24 h) induces apoptosis of SGC-7901 cells through the mitochondrial pathway mediated by ROS production and the decrease of Bcl-2/Bax ratio^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay ^[2]

Cell Line:	SGC-7901
Concentration:	5, 10, 15, 20 μM
Incubation Time:	24 h
Result:	Inhibited cell growth in a dose-dependent manner.

Apoptosis Analysis ^[2]

Cell Line:	SGC-7901
Concentration:	5, 10, 15, 20 μM
Incubation Time:	24 h
Result:	Increased the number of early apoptotic cells.

Western Blot Analysis ^[2]

Cell Line:	SGC-7901
Concentration:	5, 10, 15, 20 μM
Incubation Time:	24 h
Result:	Decreased the expression of Bcl-2 and increased the Bax protein.

In Vivo

Juglone (0.25 or 1 mg/kg, oral, 70 days) prevents metabolic endotoxemia-nduced hepatitis and neuroinflammation by inhibiting TLR4/NF-kB signaling pathway in high-fat diet rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	High-fat diet rats model^[3]
Dosage:	0.25 or 1 mg/kg
Administration:	p.o. for 70 days
Result:	Regulated the expression of s TNF-α, IL-1β and IL-6. Inhibited the TLR4 expression and NF-kappa activity.

Molecular Weight

174.16

Formula

C₁₀H₆O₃

CAS No.

481-39-0

Appearance

Solid

Color

Brown to orange

SMILES

O=C(C1=C2C=CC=C1O)C=CC2=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

Ethanol : ≥ 3.33 mg/mL (19.12 mM; DMSO can inactivate Juglone's activity)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.7418 mL	28.7092 mL	57.4185 mL
5 mM	1.1484 mL	5.7418 mL	11.4837 mL
10 mM	0.5742 mL	2.8709 mL	5.7418 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.33 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (3.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.33 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (3.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 0.33 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (3.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.77%

Select Batch:

Data Sheet (282 KB) SDS (480 KB)

COA (252 KB) HNMR (140 KB) RP-HPLC (223 KB)

Handling Instructions (2659 KB)

References

[1]. Zmantar T, et al. Use of juglone as antibacterial and potential efflux pump inhibitors in Staphylococcus aureus isolated from the oral cavity. Microb Pathog. 2016 Dec;101:44-49. [Content Brief]

[2]. Ji YB, et al. Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp Toxicol Pathol. 2011 Jan;63(1-2):69-78. [Content Brief]

[3]. Peng X, et al. Juglone prevents metabolic endotoxemia-induced hepatitis and neuroinflammation via suppressing TLR4/NF-κB signaling pathway in high-fat diet rats. Biochem Biophys Res Commun. 2015 Jul 3;462(3):245-50. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol	1 mM	5.7418 mL	28.7092 mL	57.4185 mL	143.5462 mL
	5 mM	1.1484 mL	5.7418 mL	11.4837 mL	28.7092 mL
	10 mM	0.5742 mL	2.8709 mL	5.7418 mL	14.3546 mL
	15 mM	0.3828 mL	1.9139 mL	3.8279 mL	9.5697 mL

Juglone Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Juglone481-39-05-Hydroxy-1,4-naphthalenedioneBacterialNF-κBToll-like Receptor (TLR)ApoptosisNuclear factor-κBNuclear factor-kappaBYellowPigmentblackwalnutantimicrobialInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Juglone (Synonyms: 5-Hydroxy-1,4-naphthalenedione)

Customer Review

Other Forms of Juglone:

Juglone Related Antibodies

4 Publications Citing Use of MCE Juglone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Toll-like Receptor (TLR) Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Juglone Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Juglone Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report